South Korea’s pharma industry has a valuable pool of promising drugs, but China still leads the way in out-licensing deals.

Britain's GSK and China's Jiangsu Hengrui Pharmaceuticals have agreed on a $500 million deal to develop up to a dozen new ...

The deal, which focuses first on a COPD drug GSK believes holds “best-in-class” potential, could involve a dozen medicines ...

GSK is paying $500M upfront for rights to a series of Hengrui drugs, the latest case of a pharma company looking to a Chinese ...

GSK signed a 12-asset licensing deal with Hengrui Pharma. Generic erosion on Vyvanse continued to hurt Takeda. Celltrion is ...

GSK and Hengrui Pharma signed a global deal for up to 12 drugs, including COPD therapy, with milestone payments totaling $12 billion.

Pharma giant Glaxosmithkline, which has major operations in Upper Providence and West Point, is partnering with China-based Hengrui Pharma, writes the ...

Out-licensing drugs to multinational corporations is a natural step for Chinese biotechs, but the recent rise in deals is ...

GSK will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology and inflammation.

With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking ...

At the same time, travel restrictions on GSK's finance head for China, Steve Nechelput, which had prevented him from leaving the country, are believed to have been lifted, the spokesman said.